AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02505724 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional training
Description: After completing the initial assessment, faculty randomized to the conventional training group received a link to a web-based instructional video. In addition, they were given a laparoscopic box trainer, laparoscopic instruments and sutures that they could use to practice with at their leisure.
Study NCT02505724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer-coaching
Description: Faculty randomized to the peer-coaching group received ½ hour of peer-coaching after completing the initial assessment on the simulator. Each faculty member sutured on the box trainer while being observed by his or her peer-coach. All study participants had the same peer-coach.After the coaching session, study participants received a link to the web-based video as well as the box trainer and supplies to independently practice laparoscopic suturing. Similar to individuals in the control group, no specific guidance regarding the amount of independent practice was given.
Study NCT02418754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2176-3
Study NCT02418754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)
Study NCT03724682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carry Life UF device
Description: Treatment with the Carry Life UF device compared to standard PD therapy
Study NCT01097551 — intervention group
Intervention type: DRUG
Intervention: Trinitrin
Description: Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
Study NCT01097551 — intervention group
Intervention type: DRUG
Intervention: Neosynephrine 10% collyrium
Description: Neosynephrine 10% collyrium: 2 drops
Study NCT01097551 — intervention group
Intervention type: DRUG
Intervention: Iontophoresis with acetylcholine delivery
Description: Iontophoresis with acetylcholine delivery
Study NCT04418154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin bound paclitaxel
Description: Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab, following epirubicin hydrochloride and cyclophosphamide.
Study NCT04418154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Take Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles with nanoparticlealbumin-bound paclitaxel, following epirubicin hydrochloride and cyclophosphamide.
Study NCT02904096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse injectable implant and 2% lidocaine HCL
Description: Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
Study NCT01978301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).
Study NCT01978301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
Study NCT03888287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watch Rx system
Description: The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations
Study NCT03888287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parkinson's Disease Inpatient Clinical Knowledge and Management Program
Description: Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients
Study NCT01942460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Study NCT03358173 — intervention group
Intervention type: PROCEDURE
Intervention: Conservative Treatment
Description: Conservative Treatment
Study NCT03358173 — intervention group
Intervention type: PROCEDURE
Intervention: Operative Plate Fixation
Description: Operative Plate Fixation
Study NCT03184025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dentin adhesive
Description: HEMA-containing and HEMA-free Self-Etch dentin adhesives clinical performance with or without surface sealant
Study NCT02825563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: in the fasting state
Study NCT02825563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: in the high fat diet
Study NCT02941029 — intervention group
Intervention type: OTHER
Intervention: Plasma Blood collection
Description: Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
Study NCT01276600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir
Description: 200mg of emtricitabine 300mg of tenofovir
Study NCT02439983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proprietary Nutritional Supplement
Description: 2 capsules taken by mouth with morning and evening meals.
Study NCT02439983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules taken by mouth with morning and evening meals.
Study NCT02661685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous IKDC-like cells
Description: Subject received autologous IKDC-like cells every 14 days
Study NCT01783288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Autonomic Function Testing
Description: heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.~Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed.
Study NCT01783288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Posture Study
Description: Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured \& collected in the supine (lying) and upright position for each participant.
Study NCT01783288 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measurement of Total Blood Volume
Description: Total blood volume is measured by using iodinated I-131 tagged human serum albumin.
Study NCT01783288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Capacity Test
Description: Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
Study NCT02486302 — intervention group
Intervention type: DRUG
Intervention: Etanercept
Description: Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.
Study NCT02090075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: apixaban
Description: 5 po or 2.5 po bid.
Study NCT02090075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: warfarin
Study NCT03947996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercise
Description: Stretching (30 minutes, 5 days per week, 8 weeks)
Study NCT03947996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: Walking (30 minutes, 5 days per week, 8 weeks)
Study NCT03095833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Odors
Description: Four odors are available: milk chocolate, dark chocolate, pineapple and apricot.~In addition, a neutral odor will be used clean air, a control odor transmitted during the task by the olfactometer in the same way as the other 4 odors, the only variant being that no odor will be deposited in the U-tube containing the smells. The images corresponding to the odors will be displayed after the odor has been proposed.
Study NCT03095833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visual stimulation
Description: Concerning behavioral passes, the subjects will be in front of a computer screen on which the task will be presented. For fMRI passes, the visual stimulation of the participant is done by a mirror system placed about 10 cm from the participant's eyes, allowing him to watch a translucent screen on which the visual stimuli are projected. The latter have an intensity similar to that of television images, and therefore below the maximum permitted by labor legislation. The stimuli will be projected via a video projector located at the back of the imager.
Study NCT03095833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental Task
Description: The olfactory sensitivity and the olfactory identification capacities of the subjects will be evaluated using the ETOC test. Subjects will have to define his state of hunger/satiety thanks to a questionnaire of hunger. Finally, subjects should assess the hedonic nature of the odor and the edibility of the odor source. The task to be performed will be the same for the behavioral study as for the imaging study. The subject will receive instruction from the following three: indulge yourself, the subject must think of the desire to eat the food that will be presented to him in olfactory and visual form; Be natural, the subject must act as naturally as possible; Or hold back, the subject must distance themselves from their desire to eat and control themselves. In a second step, an odor will be presented for 5 seconds. This will be based on the subject's inspiration, then an image associated with the odor will be presented for two seconds.
Study NCT03095833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood tests
Description: Before and after the imaging examination, a blood sample will be taken by a medical imaging manipulator affiliated with the CERMEP whose actions will be remunerated in accordance with the usual hygiene and safety rules. The samples taken will then be annotated with the subject code and kept at the CERMEP. The volume of ghrelin sampling is 5 ml (10 ml for two samples). The volume of the leptin is 5 ml (ie 10 ml for two samples).
Study NCT03095833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires and test administered
Description: The proposed questionnaires respond to all ethical aspects established by international and national standards to undertake studies on human subjects. Two types of questionnaires will be used in this experiment: Inclusion of the Subjects and Exploratory Tests.
Study NCT03095833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: The purpose of the imaging part is to determine how high-level cognitive control (the setpoint) can affect the price of a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
Study NCT03095833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Odors 2
Description: To modify the floral character of the wine used, the investigators will use the β-ionone odorant molecule (4 (2,6,6-trimethyl-1-cyclohexenyl) -3-buten-2-one (CAS number 14901-07-6) Purity ≥97.0% (Fluka) This molecule is commonly found in wines with a violet odor.
Study NCT03095833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Images
Description: The visual stimulation of the subject will be done by a system of mirrors placed about 10 cm from the subject's eyes allows him to look at a translucent screen behind the MRI scanner and on which the visual stimuli are projected.
Study NCT03095833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental Task fMRI
Description: For each test the subjects will receive at the same time an image on the screen and a sample of wine (2 ml) delivered in the mouth of the subject thanks to the system of programmable pumps.
Study NCT03095833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Genotyping for susceptibility to β-ionone
Description: Sampling will be done by the subject himself by scratching and firmly pressing into the oral cavity, specifically at the cheeks and tongue for one minute, being careful not to touch the teeth and gums.
Study NCT03095833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental Task 2
Description: The investigators will determine how perceptual judgments are modulated by cross-modal stimuli, as well as metacognitive judgments (how individuals judge their own sensory performance). In addition, they will determine how perceptual judgments are modified in the context of group decisions and how language influences performance.
Study NCT04393285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 150mg orally twice a day
Study NCT04393285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5mg orally once a day
Study NCT04343820 — intervention group
Intervention type: PROCEDURE
Intervention: Breast reconstruction
Description: Breast reconstruction by prepectoral positioned implant after lipo-preparation of the wall.
Study NCT02330965 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood draws (65 mLs \[\~4 tablespoons\] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
Study NCT01414816 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: EOD, dosage frequency and duration will be decide by physicians.
Study NCT00921856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracoronary acetylcholine provocation test
Description: Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
Study NCT03251651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is infused continuously via the target-controlled infusion device (Orchestra®, Fresenius vial, Brezins, France), and the effect-site concentration is maintained within 0.5-2.0 μg/ml.
Study NCT03251651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is diluted with 0.9% saline to make a concentration of 4 μg/ml. As a loading dose, 1 μg/kg dexmedetomidine is administered over a 10-min period, which is then administered continuously at 0.1-0.5 μg/kg/h.
Study NCT01234194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rising remifentanil concentrations
Description: remifentanil effect-compartment concentrations 0,1,2,3 ng/ml
Study NCT01234194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: falling remifentanil concentrations
Description: remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml
Study NCT03770624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007 tablet
Description: QL-007 will be administered orally daily over the 28 days under fasted state.
Study NCT03770624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: TDF will be administered orally daily over the 28 days e.
Study NCT02704481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200mg oral mifepristone
Study NCT02704481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 800mcg buccal misoprostol
Study NCT03641989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plaque disclosing toothpaste
Description: Plaque identifying toothpaste with a FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
Study NCT03641989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-plaque disclosing toothpaste
Description: Toothpaste that does not contain the FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
Study NCT02702908 — intervention group
Intervention type: OTHER
Description: Historical Reference group.
Study NCT01097551 — intervention group
Intervention type: DEVICE
Intervention: Dynamic Vessel Analyzer
Description: Dynamic Vessel Analyzer
Study NCT01047033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: 30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.
Study NCT01047033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microcredit
Description: Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
Study NCT01047033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microcredit
Description: Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
Study NCT03365791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
Study NCT03365791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAG525
Description: LAG525 is a high-affinity, ligand-blocking, humanized anti-LAG-3 IgG4 antibody which blocks the binding of the known LAG-3 ligand MHC class II to LAG-3.
Study NCT03558035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction CT+ CRT group
Description: Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
Study NCT03558035 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent CRT group
Description: cisplatin 100mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
Study NCT02714296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutridrink 200 ml
Description: Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
Study NCT02714296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutridrink compact protein
Description: 2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
Study NCT04226586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Essential Amino Acid (EAA) group
Description: Eligible children will be supplemented with Essential Amino Acids (EAA) for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
Study NCT04226586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible children will be supplemented with a placebo for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
Study NCT00131482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chrysalin
Description: Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
Study NCT00131482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chrysalin
Description: Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
Study NCT00131482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chrysalin
Description: Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
Study NCT00131482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chrysalin
Description: Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
Study NCT00131482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
Study NCT01978691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis ssp. lactis 420
Description: Studied as a probiotic bacteria
Study NCT01978691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polydextrose
Description: Studied as a prebiotic
Study NCT01978691 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control
Study NCT01583634 — intervention group
Intervention type: DEVICE
Intervention: Mespere Oximeter
Description: Mespere oximeter provides non-invasive venous blood oxygen saturation.
Study NCT01583634 — intervention group
Intervention type: DEVICE
Intervention: Radiometer OSM-3 Co-Oximeter
Description: OSM-3, a Radiometer manufactured hemoximeter, is intended for the photometric determination of hemoglobin.
Study NCT04598633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)
Description: Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
Study NCT04598633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-lozenges (BioGaia)
Description: Placebo-lozenges (BioGaia) 2 times per day for 12 weeks
Study NCT01831986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pregnenolone and L-Theanine
Description: Pregnenolone (50 mg/day) with L-theanine (400 mg/day)